TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
Catherine AngwinCaroline JenkinsonAngus G JonesChristopher JennisonWilliam HenleyAndrew J FarmerNaveed SattarRury R HolmanEwan PearsonBeverley M ShieldsAndrew Hattersleynull nullPublished in: BMJ open (2020)
12039221; 2015-002790-38 and NCT02653209.